<DOC>
	<DOCNO>NCT02250482</DOCNO>
	<brief_summary>The main objective study investigate safety efficacy Optivate® , administer appropriate dosage present bleed achieve haemostasis patient Haemophilia A undergoing surgery .</brief_summary>
	<brief_title>An Open Study Investigate Safety Efficacy Optivate® Haemophilia A Patients Undergoing Surgery .</brief_title>
	<detailed_description />
	<mesh_term>Hemophilia A</mesh_term>
	<mesh_term>Factor VIII</mesh_term>
	<criteria>Diagnosed Haemophilia A , least 12 year age , due undergo surgery lifetime exposure least 20 exposure FVIII concentrate .</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2014</verification_date>
</DOC>